A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension

American Journal of Ophthalmology

Volumn 122, Issue 2, 1996, Pages 183-194

  Strahlman, E ^a   Tipping, R ^a   Vogel, R ^a   Abrantes, P ^a   Alm, A ^a   Airaksinen, P J ^a   Barnebey, H ^a   Borgeois, A ^a   Cohen, J S ^a   Collignon Brach, J ^a   Cyrlin, M N ^a   Demailly, P ^a   Ehinger, B ^a   George, J L ^a   Greve, E ^a   Gross, R L ^a   Higginbotham, E J ^a   Kass, M A ^a   Laibovitz, R A ^a  

^a BAUSCH AND LOMB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE INHIBITOR; DIPIVEFRINE; DORZOLAMIDE; PILOCARPINE; PLACEBO; TIMOLOL;

ADULT; AGED; ARTICLE; BURN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; FOREIGN BODY REACTION; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; TOPICAL DRUG ADMINISTRATION; VISUAL IMPAIRMENT;

EID: 9444268112     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(14)72009-4     Document Type: Article

References (13)

1. Wang RF Serle JB Podos SM Sugrue MF MK-507 (L-671,152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys Arch Ophthalmol 109 1991 1297 1299
2. Lippa EA Carlson LE Ehinger B Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor Arch Ophthalmol 110 1992 495 499
3. Lippa EA Schuman JS Higginbotham EJ MK-507 versus sezolamide: comparative efficacy of two topically active carbonic anhydrase inhibitors Ophthalmology 98 1991 308 312
4. Wilkerson M Cyrlin M Lippa EA Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor Arch Ophthalmol 111 1993 1343 1350
5. Nardin G Lewis RA Lippa EA Activity of the topical CAI MK-507 b.i.d. when added to timolol b.i.d. ARVO Abstracts Invest Ophthalmol Vis Sci 32 1991 989 (suppl)
6. Jonckheere AR A distribution-free K-sample test against ordered alternatives Biometrika 41 1954 133 145
7. Peto R Peto J Asymptotically efficient rank invariant test procedures J R Stat Soc Series A 135 1972 185 207
8. Strahlman ER, Deasy D, Panebianco D, Timolol/Dorzolamide Combination Study Group. A two-week pilot activity study of a fixed combination of timolol and dorzolamide hydrochloride. ARVO Abstracts. Invest Ophthalmol Vis Sci 1993;34(suppl):1148
9. Boozman FW Foerster RI Allen RC The long-term efficacy of twice-daily 0.25% levobunolol and timolol Arch Ophthalmol 106 1988 614 618
10. Long D Zimmerman T Spaeth G Novack G Burke PJ Duzman E Minimum concentration of levobunolol required to control intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension Am J Ophthalmol 99 1985 18 22
11. Kass MA Gordon MO Hoff MR Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals Arch Ophthalmol 107 1989 1590 1598
12. Buclin T Biollaz J Lippa EA Absence of metabolic effects of the topical carbonic anhydrase inhibitors MK-927 and sezolamide during two-week ocular administration to normal subjects Clin Pharmacol Ther 49 1991 665 673
13. Strahlman ER Tipping R Vogel R A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol and betaxolol Arch Ophthalmol 113 1995 1009 1016